Tharimmune Inc. Cash Flow Conversion Efficiency
Tharimmune Inc. cash flow conversion efficiency. Based on the latest financial reports, Tharimmune Inc. (THAR) has a cash flow conversion efficiency ratio of -0.016x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.64 Million) by net assets ($469.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Tharimmune Inc. (2019–2025)
Cash flow conversion efficiency of Tharimmune Inc. from 2019 to 2025. This chart illustrates how Tharimmune Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View THAR stock price for real-time trading data and today's change.
Tharimmune Inc. Cash Flow Conversion Ratio Explained
Tharimmune Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Tharimmune Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tharimmune Inc. ranked by their cash flow conversion efficiency. Also see Tharimmune Inc. (THAR) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GREENLAND RESOURCES INC.
F:M0LY
|
-0.139x |
|
Avalo Therapeutics Inc
NASDAQ:AVTX
|
-0.179x |
|
Smith-Midland Corp
NASDAQ:SMID
|
-0.009x |
|
Cyberlink Co
TW:5203
|
-0.032x |
|
Impiana Hotels Bhd
KLSE:7243
|
-0.111x |
|
PRECIA SA EO -50
F:P1E0
|
N/A |
|
Hannong Chem
KO:011500
|
0.058x |
|
Bastogi S.p.A
F:BAOA
|
0.002x |
Annual Cash Flow Conversion Efficiency for Tharimmune Inc. (2019–2025)
The table below shows the annual cash flow conversion efficiency of Tharimmune Inc. from 2019 to 2025. Review financial agility of Tharimmune Inc. to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $397.93 Million | $-16.13 Million | -0.041x | +99.51% |
| 2024-12-31 | $1.31 Million | $-10.90 Million | -8.337x | -942.85% |
| 2023-12-31 | $9.13 Million | $-7.30 Million | -0.799x | +32.42% |
| 2022-12-31 | $5.54 Million | $-6.56 Million | -1.183x | -610.21% |
| 2021-12-31 | $-4.68 Million | $-1.09 Million | 0.232x | -20.07% |
| 2020-12-31 | $-3.72 Million | $-1.08 Million | 0.290x | -33.35% |
| 2019-12-31 | $-1.62 Million | $-706.11K | 0.435x | -- |
About Tharimmune Inc.
Tharimmune, Inc. focuses on leveraging Canton Coin and supporting the Canton network to advance institutional blockchain adoption and the digitization of financial markets. It is also involved in the clinical-stage biotech research and development activities. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. w… Read more